ESR1 and neoplasm: Thus, considering that trastuzumab and/or pertuzumab combined with taxane-based chemotherapy provides pCR rates as high as 60%, and reaches 75% in HER2+/ER- tumours, this regimen stands as the neoadjuvant standard therapy [31].